CRL

MKT CAP:$8B

Charles River Laboratories International, Inc.

Market Cap

$8B

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NYSE

Healthcare·Medical·🇺🇸·NYSE

Stock Price

$183.10-$19.32 (-9.54%)

Apr 21, 2026

Company Details

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and intern...

CEO

James C. Foster

IPO Date

Jun 23, 2000

Website

www.criver.com

Key Metrics TTM

Revenue

$4.0B

+41.1% YoY

Net Income

$32M

EPS (Diluted)

$0.40

Free Cash Flow

$188M

Revenue / Share

$80.99

Gross Margin

35.4%

Operating Margin

15.7%

Net Margin

0.8%

FCF Margin

4.7%

P/S

2.1x

P/E

256.3x

Earnings Reports

Q1 2026

May 6, 2026

PENDING

Q4 2025

Feb 18, 2026

$994MEPS -$5.62

Q1 2023

May 11, 2023

$1.0BEPS $2.01

Q3 2022

Nov 2, 2022

$989MEPS $1.88

Q2 2022

Aug 3, 2022

$973MEPS $2.13

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 16	$426M	$156M	$59M
Q1 17	$446M	$171M	$70M
Q4 19	$691M	$262M	$109M
Q1 20	$707M	$252M	$94M
Q2 20	$683M	$232M	$77M
Q3 20	$743M	$289M	$133M
Q2 22	$973M	$357M	$187M
Q3 22	$989M	$370M	$151M
Q1 23	$1.0B	$378M	$168M
Q4 25	$994M	$308M	$120M

Valuation

Quarter	P/S	P/E
Q3 16	—	—
Q1 17	—	—
Q4 19	—	—
Q1 20	3.7x	38.5x
Q2 20	3.3x	33.8x
Q3 20	2.9x	27.5x
Q2 22	2.7x	25.1x
Q3 22	2.4x	22.1x
Q1 23	2.2x	20.1x
Q4 25	2.1x	256.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 16	$69M	$59M
Q1 17	$34M	$18M
Q4 19	$181M	$117M
Q1 20	$69M	$43M
Q2 20	$162M	$136M
Q3 20	$177M	$151M
Q2 22	$149M	$67M
Q3 22	$133M	$60M
Q1 23	$109M	$3M
Q4 25	$148M	$59M

Capital Expenditures

Quarter	CapEx
Q3 16	$10M
Q1 17	$16M
Q4 19	$64M
Q1 20	$26M
Q2 20	$27M
Q3 20	$26M
Q2 22	$83M
Q3 22	$72M
Q1 23	$107M
Q4 25	$89M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 20	+60.3%	+65.1%
Q3 20	+66.7%	+62.4%
Q2 22	+40.8%	+34.9%
Q3 22	+39.9%	+36.8%
Q1 23	+50.8%	+42.2%
Q4 25	+33.8%	+43.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 16	$11M	2.5%
Q1 17	$9M	2.1%
Q4 19	$14M	2.0%
Q1 20	$11M	1.6%
Q2 20	$13M	1.9%
Q3 20	$17M	2.3%
Q2 22	$15M	1.5%
Q3 22	$22M	2.2%
Q1 23	$13M	1.3%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	SG&A
Q3 16	$86M
Q1 17	$91M
Q4 19	$130M
Q1 20	$130M
Q2 20	$128M
Q3 20	$128M
Q2 22	$132M
Q3 22	$184M
Q1 23	$175M
Q4 25	$188M

Revenue Segments

Quarter	Discovery and Safety Assessment	Manufacturing Support	Research Models and Services
Q3 16	$216M	$89M	$121M
Q1 17	$228M	$91M	$127M
Q1 20	$439M	$122M	$146M
Q2 20	$443M	$123M	$117M
Q3 20	$461M	$130M	$152M
Q3 22	$664M	$176M	$187M
Q1 23	$662M	$167M	$200M
Q4 25	$592M	$196M	$206M

Revenue by Geography

Quarter	Asia Pacific	Canada	Europe	United States
Q1 20	$32M	$77M	$190M	$407M
Q2 20	$36M	$72M	$191M	$383M
Q3 20	$42M	$79M	$214M	$407M
Q2 22	$46M	$94M	$264M	$567M
Q3 22	$44M	$102M	$246M	$595M
Q1 23	$43M	$111M	$268M	$605M
Q4 25	$57M	$123M	$280M	$517M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$242M	$1M	$243M
Q2 22	$206M	$1M	$207M
Q3 22	$194M	$950.0K	$195M
Q4 22	$234M	$0	$234M
Q1 23	$202M	$0	$202M
Q2 23	$200M	$0	$200M
Q3 23	$157M	$0	$157M
Q4 23	$277M	$0	$277M
Q1 24	$327M	$0	$327M
Q2 24	$179M	$0	$179M
Q3 24	$210M	$0	$210M
Q4 24	$195M	$0	$195M
Q1 25	$229M	$0	$229M
Q2 25	$183M	$0	$183M
Q3 25	$208M	$0	$208M
Q4 25	$214M	$0	$214M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 16	48M	—	—
Q1 17	48M	+0.8%	—
Q4 19	50M	+3.0%	—
Q1 20	50M	+0.2%	—
Q2 20	50M	+0.6%	+4.6%
Q3 20	51M	+0.9%	+4.7%
Q2 22	51M	+1.1%	+2.8%
Q3 22	51M	0.0%	+2.6%
Q1 23	51M	+0.3%	+2.4%
Q4 25	49M	-4.3%	-2.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 16	$49.5K	9K
Q1 17	$40.5K	11K
Q4 19	$40.4K	17K
Q1 20	$41.3K	17K
Q2 20	$39.9K	17K
Q3 20	$43.5K	17K
Q2 22	$48.7K	20K
Q3 22	$49.5K	20K
Q1 23	$48.1K	21K
Q4 25	$50.5K	20K

Revenue / Employee